Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 -11.46 (-4.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

23 24 Next >

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

January 09, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates

January 07, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

Analyst Expectations for Alnylam Pharmaceuticals's Future ↗

December 08, 2023

Via Benzinga

Expert Ratings for Alnylam Pharmaceuticals ↗

November 15, 2023

Via Benzinga

Earnings Outlook For Alnylam Pharmaceuticals ↗

November 01, 2023

Via Benzinga

Expert Ratings for Alnylam Pharmaceuticals ↗

October 16, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

December 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

Alnylam to Webcast Virtual R&D Day

December 06, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Why Newly Listed Korro Bio Shares Are Gaining Today ↗

December 04, 2023

H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.

Via Benzinga

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

November 30, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

November 11, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws ↗

November 08, 2023

San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 07, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity

November 02, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year

October 26, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

October 25, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

October 25, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results

October 19, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

October 11, 2023

Via Benzinga

CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

October 11, 2023

Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗

October 11, 2023

Via Benzinga

Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today? ↗

October 09, 2023

The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin-

Via Benzinga

Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug ↗

October 09, 2023

Shares skidded to their lowest point since September on the FDA's rejection.

Via Investor's Business Daily

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.